A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations

Morton W. Miller; E. Carr Everbach; C. Cox; Ryan R. Knapp; Andrew A. Brayman; Teresa A. Sherman

doi:10.1016/S0301-5629(01)00356-8

A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations

Morton W. Miller, E. Carr Everbach, C. Cox, Ryan R. Knapp, Andrew A. Brayman, Teresa A. Sherman

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison™), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex®), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P^-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison™/Albunex® regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.

Original language	English (US)
Pages (from-to)	709-721
Number of pages	13
Journal	Ultrasound in Medicine and Biology
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/S0301-5629(01)00356-8
State	Published - 2001
Externally published	Yes

Keywords

Albunex®
Hemolysis in vitro
Optison™
Passive cavitation detection
Ultrasound

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Biophysics
Acoustics and Ultrasonics

Access to Document

10.1016/S0301-5629(01)00356-8

Cite this

Miller, M. W., Everbach, E. C., Cox, C., Knapp, R. R., Brayman, A. A., & Sherman, T. A. (2001). A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations. Ultrasound in Medicine and Biology, 27(5), 709-721. https://doi.org/10.1016/S0301-5629(01)00356-8

A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations. / Miller, Morton W.; Everbach, E. Carr; Cox, C. et al.
In: Ultrasound in Medicine and Biology, Vol. 27, No. 5, 2001, p. 709-721.

Research output: Contribution to journal › Article › peer-review

Miller, MW, Everbach, EC, Cox, C, Knapp, RR, Brayman, AA & Sherman, TA 2001, 'A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations', Ultrasound in Medicine and Biology, vol. 27, no. 5, pp. 709-721. https://doi.org/10.1016/S0301-5629(01)00356-8

@article{45fba88ef3ce4e48a687af56eae25083,

title = "A comparison of the hemolytic potential of Optison{\texttrademark} and Albunex{\textregistered} in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations",

abstract = "This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison{\texttrademark}), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex{\textregistered}), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison{\texttrademark}/Albunex{\textregistered} regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.",

keywords = "Albunex{\textregistered}, Hemolysis in vitro, Optison{\texttrademark}, Passive cavitation detection, Ultrasound",

author = "Miller, {Morton W.} and Everbach, {E. Carr} and C. Cox and Knapp, {Ryan R.} and Brayman, {Andrew A.} and Sherman, {Teresa A.}",

note = "Funding Information: The authors thank Mallinckrodt, Inc., St. Louis, MO for the gratuitous provision of Albunex{\textregistered} and Optison{\texttrademark}. This research project was supported by NIH grant R37CA39250–26 to Morton W. Miller and NSF Presidential Faculty Fellowship MSS92537777 to E. Carr Everbach. ",

year = "2001",

doi = "10.1016/S0301-5629(01)00356-8",

language = "English (US)",

volume = "27",

pages = "709--721",

journal = "Ultrasound in Medicine and Biology",

issn = "0301-5629",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro

T2 - Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations

AU - Miller, Morton W.

AU - Everbach, E. Carr

AU - Cox, C.

AU - Knapp, Ryan R.

AU - Brayman, Andrew A.

AU - Sherman, Teresa A.

N1 - Funding Information: The authors thank Mallinckrodt, Inc., St. Louis, MO for the gratuitous provision of Albunex® and Optison™. This research project was supported by NIH grant R37CA39250–26 to Morton W. Miller and NSF Presidential Faculty Fellowship MSS92537777 to E. Carr Everbach.

PY - 2001

Y1 - 2001

N2 - This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison™), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex®), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison™/Albunex® regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.

AB - This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison™), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex®), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison™/Albunex® regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.

KW - Albunex®

KW - Hemolysis in vitro

KW - Optison™

KW - Passive cavitation detection

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0035009803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035009803&partnerID=8YFLogxK

U2 - 10.1016/S0301-5629(01)00356-8

DO - 10.1016/S0301-5629(01)00356-8

M3 - Article

C2 - 11397535

AN - SCOPUS:0035009803

SN - 0301-5629

VL - 27

SP - 709

EP - 721

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

IS - 5

ER -

A comparison of the hemolytic potential of Optison™ and Albunex® in whole human blood in vitro: Acoustic pressure, ultrasound frequency, donor and passive cavitation detection considerations

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this